Lawitz, E; Gane, E; Pearlman, B; Tam, E; Ghesquiere, W; Guyader, D; Alric, L; Bronowicki, JP et al. (2015). «Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial». Lancet385 (9973): 1075-86. PMID25467591. doi:10.1016/S0140-6736(14)61795-5.Se sugiere usar |número-autores= (ayuda)
Coburn, CA; Meinke, PT; Chang, W; Fandozzi, CM; Graham, DJ; Hu, B; Huang, Q; Kargman, S et al. (2013). «Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity». ChemMedChem8 (12): 1930-40. PMID24127258. doi:10.1002/cmdc.201300343.Se sugiere usar |número-autores= (ayuda)
Gentile, I; Buonomo, AR; Zappulo, E; Borgia, G (Jul 2014). «Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?». Expert Review of Anti-Infective Therapy12 (7): 763-73. PMID24918116. doi:10.1586/14787210.2014.929497.
Lawitz, E; Gane, E; Pearlman, B; Tam, E; Ghesquiere, W; Guyader, D; Alric, L; Bronowicki, JP et al. (2015). «Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial». Lancet385 (9973): 1075-86. PMID25467591. doi:10.1016/S0140-6736(14)61795-5.Se sugiere usar |número-autores= (ayuda)
Coburn, CA; Meinke, PT; Chang, W; Fandozzi, CM; Graham, DJ; Hu, B; Huang, Q; Kargman, S et al. (2013). «Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity». ChemMedChem8 (12): 1930-40. PMID24127258. doi:10.1002/cmdc.201300343.Se sugiere usar |número-autores= (ayuda)
Gentile, I; Buonomo, AR; Zappulo, E; Borgia, G (Jul 2014). «Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?». Expert Review of Anti-Infective Therapy12 (7): 763-73. PMID24918116. doi:10.1586/14787210.2014.929497.